NATCO PHARMA
Back to Balance Sheet
|
NATCO PHARMA Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹944 Cr | ₹973 Cr | ₹683 Cr | ₹710 Cr | ₹526 Cr |
What is the latest Total Current Liabilities ratio of NATCO PHARMA ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹944 Cr |
| Mar2024 | ₹973 Cr |
| Mar2023 | ₹683 Cr |
| Mar2022 | ₹710 Cr |
| Mar2021 | ₹526 Cr |
How is Total Current Liabilities of NATCO PHARMA Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹944 Cr | -3.01 | |
| Mar2024 | ₹973 Cr | 42.41 | |
| Mar2023 | ₹683 Cr | -3.84 | |
| Mar2022 | ₹710 Cr | 35.16 | |
| Mar2021 | ₹526 Cr | - | |
Compare Total Current Liabilities of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹20,040.4 Cr | 1.4% | 17% | 45.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹401,937.0 Cr | 1.2% | -7% | 2.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹165,359.0 Cr | 1.8% | 2.7% | 17% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹141,431.0 Cr | 0.5% | -4.8% | 32.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹103,114.0 Cr | 0.3% | -4.5% | 11.5% | Stock Analytics | |
| CIPLA | ₹100,028.0 Cr | 0.7% | -5.8% | -13.1% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | 1.4% |
17% |
45.6% |
| SENSEX | 2.4% |
3.2% |
5.8% |
You may also like the below Video Courses